Epigenomics AG Successfully Completes First Step Towards Lung Cancer Screening Test Development
05 oct. 2006 02h39 HE
|
Epigenomics AG
-- Many novel candidate DNA methylation biomarkers discovered
-- Candidate biomarkers broadly applicable to major subtypes of lung
cancer
-- Clinical validation studies in blood to begin...
Epigenomics Announces Change in the Executive Board
17 août 2006 18h57 HE
|
Epigenomics AG
BERLIN, Aug. 17, 2006 (PRIMEZONE) -- The Supervisory Board of Epigenomics AG and the Chief Executive Officer and founder Alexander Olek have unanimously agreed that his service contract as well as his...
Epigenomics AG Enters Into Agreement With Johnson & Johnson Pharmaceutical Research & Development, L.L.C
07 août 2006 09h34 HE
|
Epigenomics AG
BERLIN, Aug. 7, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) has entered into an R&D collaboration with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)...
Epigenomics AG Reports Second Quarter 2006 Financial Results
03 août 2006 09h12 HE
|
Epigenomics AG
BERLIN, Aug. 3, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt, Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, today reported financial results for the...
Hugin Ad Hoc Announcement According to Section 15 WpHG: Capital Increase: Epigenomics AG: Epigenomics AG Decides Capital Increase -- Affymetrix Signs for New Shares
21 juil. 2006 09h55 HE
|
Epigenomics AG
BERLIN, July 21, 2006 (PRIMEZONE) -- Epigenomics' Management Board decided with the approval of the Supervisory Board on July 20, 2006, to increase the signed capital of the company by making partial...
Epigenomics AG Presents New Clinical Data on Colorectal Cancer Screening Markers
05 juil. 2006 09h49 HE
|
Epigenomics AG
BERLIN and SEATTLE, July 5, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, is presenting new...
Hugin Ad hoc Announcement According to No. 15 WpHG: License: Epigenomics AG: Epigenomics AG and Affymetrix Announce Strategic Diagnostics Platform Agreement
27 juin 2006 12h24 HE
|
Epigenomics AG
SANTA CLARA, Calif., BERLIN and SEATTLE, June 27, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation,...
Epigenomics AG and Wellcome Trust Sanger Institute Release Epigenetic Data on the First 3 Chromosomes
26 juin 2006 13h28 HE
|
Epigenomics AG
BERLIN and SEATTLE, June 26, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, and the Wellcome Trust...
Epigenomics AG Announces Research Collaboration with Stanford University
08 juin 2006 15h09 HE
|
Epigenomics AG
BERLIN, Germany and SEATTLE, June 8, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that the company has...
Epigenomics AG Announces Continuation of Pharmaceutical Biomarker Research Collaboration with AstraZeneca in the Field of Oncology
16 mai 2006 09h16 HE
|
Epigenomics AG
BERLIN and SEATTLE, May 16, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that the...